Citation Tools

Download PDFPDF
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

Download to a citation manager

Cite this article as:
Plasencia C, Pascual-Salcedo D, Alcocer P, et al
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab